Myriad Genetics, MYGN

Analyst Sees Bottom For Myriad Genetics Stock, Issues Upgrade
Piper Sandler upgrades Myriad Genetics to Overweight, citing stock stabilization and new leadership. The firm raises its price target to $12.50.
Piper Sandler Upgrades Myriad Genetics (MYGN)
Fintel reports that on March 12, 2025, Piper Sandler upgraded their outlook for Myriad Genetics (NasdaqGS:MYGN) from Neutral to Overweight. Analyst Price Forecast Suggests 84.10% Upside As of March 4,
Why Are Myriad Genetics (MYGN) Shares Soaring Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 10.6% in the morning session after Piper Sandler analysts upgraded the stock's rating from Neutral to Buy. The improved outlook was based on expectations for MYGN's new CEO,
Myriad Genetics upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Myriad Genetics (MYGN) to Overweight from Neutral with a price target of $12.50, up from $11.50. The stock is down more
Myriad Genetics upgraded at Piper Sandler on balanced risk reward setup
Myriad Genetics (MYGN) stock was upgraded to Overweight by Piper Sandler, citing a balanced risk-reward set up for its beaten-down shares. Read more here.
Why Myriad Genetics (MYGN) Shares Are Plunging Today
Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 16.1% in the morning session after the company reported a tough quarter(Q4 2024), with revenue missing expectations and 2025 guidance for both revenue and EBITDA coming in light.
Myriad Genetics price target lowered to $16 from $21 at Morgan Stanley
Morgan Stanley lowered the firm’s price target on Myriad Genetics (MYGN) to $16 from $21 and keeps an Equal Weight rating on the shares after ...
Schaeffer's Investment Research1d
Medical Equipment Stock Jumps on Upgrade
Short sellers have been increasing their bets, with short interest now accounting for 6.1% of the stock's available float.
Myriad Genetics Faces Cost Restructuring As UnitedHealthcare Ends GeneSight Coverage, Appoints New CEO
UnitedHealthcare will stop covering Myriad Genetics' GeneSight test in 2025, impacting $45 million in revenue. Myriad ...
Myriad Genetics and Gabbi to Work Together to Increase Access to Hereditary Cancer Risk Assessment Tools
Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostics testing and precision medicine, today announced a ...
CNN10d
Myriad Genetics, Inc.
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic tests. It operates through the Diagnostics and Other segments. The Diagnostics ...
ETF Daily News4d
Myriad Genetics, Inc. (NASDAQ:MYGN) Receives $21.82 Average Price Target from Analysts
Myriad Genetics has a 1-year low of $9.76 and a 1-year high of $29.30. Myriad Genetics ( NASDAQ:MYGN – Get Free Report ) last issued its earnings results on Tuesday, February 25th.